A quick peek into the report
Table of Contents
1.1 Inclusion and Exclusion Criteria
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
4.1 Introduction to Gene Fusion Testing
4.1.1 Different Technologies for Gene Fusion Testing
4.1.2 Advantages and Limitations of Gene Fusion Testing
4.1.3 Current Market Size and Future Growth Potential, $Million, 2023-2035
4.1.4 Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
4.1.5 Reimbursement Landscape
4.2 Stakeholder’s Survey Response
4.2.1 Awareness of Gene Fusion Testing
4.2.2 Familiarity with the NGS Offerings of the Following Companies
4.2.3 Adoption and Barriers for Gene Fusion Testing
5.1 Regulatory Landscape
5.1.1 Legal Requirements and Frameworks in the U.S.
5.1.2 Legal Requirements and Frameworks in Europe
5.1.3 Legal Requirements and Frameworks in Asia-Pacific
5.1.3.1 Legal Requirements and Framework in China
5.1.3.2 Legal Requirements and Framework in Japan
6.1 Impact Analysis
6.2 Market Drivers
6.3 Market Restraints
6.4 Market Opportunities
7.1 Overview
7.2 Key Strategies and Developments
7.2.1 Product Approvals and Launches
7.2.2 Partnerships and Collaborations
7.2.3 Mergers and Acquisitions
7.2.4 Other Developments
7.3 Market Share Analysis
7.3.1 By Company
7.4 Growth-Share Analysis
8.1 Overview
8.2 Research
8.3 Diagnostic
9.1 Overview
9.2 Next-Generation Sequencing (NGS)
9.3 Fluorescence In-Situ Hybridization (FISH)
9.4 Polymerase Chain Reaction (PCR)
9.5 Immunohistochemistry (IHC)
10.1 Overview
10.2 Solid Tumors
10.2.1 Lung Cancer
10.2.2 Breast Cancer
10.2.3 Colorectal Cancer
10.2.4 Thyroid Cancer
10.2.5 Others
10.3 Hematological Malignancies
11.1 Overview
11.2 Pharmaceutical and Biotechnology Companies
11.3 Hospitals and Diagnostic Laboratories
11.4 Research and Academic Centers
12.1 Overview
12.2 North America
12.2.1 North America Gene Fusion Testing Market, by Indication
12.2.2 North America Gene Fusion Testing Market (by Country)
12.2.2.1 U.S.
12.2.2.1.1 U.S. Gene Fusion Testing Market (by Indication)
12.2.2.2 Canada
12.2.2.2.1 Canada Gene Fusion Testing Market (by Indication)
12.3 Europe
12.3.1 Europe Gene Fusion Testing Market, by Indication
12.3.2 Europe Gene Fusion Testing Market (by Country)
12.3.2.1 Germany
12.3.2.1.1 Germany Gene Fusion Testing Market (by Indication)
12.3.2.2 France
12.3.2.2.1 France Gene Fusion Testing Market (by Indication)
12.3.2.3 U.K.
12.3.2.3.1 U.K. Gene Fusion Testing Market (by Indication)
12.3.2.4 Italy
12.3.2.4.1 Italy Gene Fusion Testing Market (by Indication)
12.3.2.5 Spain
12.3.2.5.1 Spain Gene Fusion Testing Market (by Indication)
12.3.2.6 Netherlands
12.3.2.6.1 Netherlands Gene Fusion Testing Market (by Indication)
12.3.2.7 Rest-of-the-Europe
12.3.2.7.1 Rest-of-the-Europe Gene Fusion Testing Market (by Indication)
12.4 Asia-Pacific
12.4.1 Asia-Pacific Gene Fusion Testing Market, by Indication
12.4.2 Asia-Pacific Gene Fusion Testing Market (by Country)
12.4.2.1 China
12.4.2.1.1 China Gene Fusion Testing Market (by Indication)
12.4.2.2 Japan
12.4.2.2.1 Japan Gene Fusion Testing Market (by Indication)
12.4.2.3 India
12.4.2.3.1 India Gene Fusion Testing Market (by Indication)
12.4.2.4 Australia
12.4.2.4.1 Australia Gene Fusion Testing Market (by Indication)
12.4.2.5 South Korea
12.4.2.5.1 South Korea Fusion Testing Market (by Indication)
12.4.2.6 Rest-of-Asia-Pacific
12.4.2.6.1 Rest-of-Asia-Pacific Gene Fusion Testing Market (by Indication)
12.5 Latin America
12.5.1 Latin America Gene Fusion Testing Market, by Indication
12.5.2 Latin America Gene Fusion Testing Market (by Country)
12.5.2.1 Brazil
12.5.2.1.1 Brazil Gene Fusion Testing Market (by Indication)
12.5.2.2 Mexico
12.5.2.2.1 Mexico Gene Fusion Testing Market (by Indication)
12.5.2.3 Rest-of-Latin America
12.5.2.3.1 Rest-of-Latin America Gene Fusion Testing Market (by Indication)
12.6 Rest-of-the-World
12.6.1 Rest-of-the-World Gene Fusion Testing Market (by Indication)
13.1 Competitive Landscape
13.1.1 New Offerings
13.1.2 Mergers and Acquisitions
13.1.3 Partnerships, Alliances, and Business Expansion
13.1.4 Funding Activities
13.1.5 Regulatory Approvals
13.2 Amoy Diagnostics Co., Ltd.
13.2.1 Overview
13.2.2 Type Portfolio
13.2.3 Target Customers
13.2.4 Key Professionals
13.2.5 Analyst View
13.3 Arima Genomics
13.3.1 Overview
13.3.2 Product Portfolio
13.3.3 Target Customers
13.3.4 Key Professionals
13.3.5 Analyst View
13.4 Biocartis
13.4.1 Overview
13.4.2 Product Portfolio
13.4.3 Target Customers
13.4.4 Key Professionals
13.4.5 Analyst View
13.5 Biocare Medical, LLC
13.5.1 Overview
13.5.2 Product Portfolio
13.5.3 Target Customers
13.5.4 Key Professionals
13.5.5 Analyst View
13.6 Bio-Rad Laboratories, Inc.
13.6.1 Overview
13.6.2 Product Portfolio
13.6.3 Target Customers
13.6.4 Key Professionals
13.6.5 Analyst View
13.7 F. Hoffmann-La Roche Ltd
13.7.1 Overview
13.7.2 Product Portfolio
13.7.3 Target Customers
13.7.4 Key Professionals
13.7.5 Analyst View
13.8 Guardant Health, Inc
13.8.1 Overview
13.8.2 Product Portfolio
13.8.3 Target Customers
13.8.4 Key Professionals
13.8.5 Analyst View
13.9 Illumina, Inc.
13.9.1 Overview
13.9.2 Product Portfolio
13.9.3 Target Customers
13.9.4 Key Professionals
13.9.5 Analyst View
13.1 Invitae Corporation
13.10.1 Overview
13.10.2 Product Portfolio
13.10.3 Target Customers
13.10.4 Key Professionals
13.10.5 Analyst View
13.11 Myriad Genetics, Inc.
13.11.1 Overview
13.11.2 Product Portfolio
13.11.3 Target Customers
13.11.4 Key Professionals
13.11.5 Analyst View
13.12 NeoGenomics, Inc.
13.12.1 Overview
13.12.2 Product Portfolio
13.12.3 Target Customers
13.12.4 Key Professionals
13.12.5 Analyst View
13.13 OncoDNA
13.13.1 Overview
13.13.2 Product Portfolio
13.13.3 Target Customers
13.13.4 Key Professionals
13.13.5 Analyst View
13.14 PerkinElmer, Inc.
13.14.1 Overview
13.14.2 Product Portfolio
13.14.3 Target Customers
13.14.4 Key Professionals
13.14.5 Analyst View
13.15 QIAGEN N.V.
13.15.1 Overview
13.15.2 Product Portfolio
13.15.3 Target Customers
13.15.4 Key Professionals
13.15.5 Analyst View
13.16 Thermo Fisher Scientific Inc.
13.16.1 Overview
13.16.2 Product Portfolio
13.16.3 Target Customers
13.16.4 Key Professionals
13.16.5 Analyst View
Table: Global Gene Fusion Testing Market Dynamics, Impact Analysis
Table: Global Gene Fusion Testing Market (by Category), $Million, 2023-2035
Table: Global Gene Fusion Testing Market (by Technology), $Million, 2023-2035
Table: Global Gene Fusion Testing Market (by Indication), $Million, 2023-2035
Table: Global Gene Fusion Testing Market (by End User), $Million, 2023-2035
Figure: Global Gene Fusion Testing Market, Dynamics Impact Analysis
Figure: Global Gene Fusion Testing Market Coverage
Figure: Global Gene Fusion Testing Market, Key Trends, Impact Analysis, 2023-2035
Figure: Global Gene Fusion Testing Market, Patent Analysis, January 2022-March 2025
Figure: Global Gene Fusion Testing Market, Competitive Landscape, January 2022-March 2025
Gene Fusion Testing Market Report Coverage
|
Gene Fusion Testing Market |
|||
|
Base Year |
2024 |
Market Size in 2024 |
$XX Billion |
|
Forecast Period |
2025-2035 |
Value Projection and Estimation by 2035 |
$XX Billion |
|
CAGR During Forecast Period |
12.5% |
|
|
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.
Some of the prominent companies in this market are:
• Amoy Diagnostics Co., Ltd.
• Biocartis
• Biocare Medical, LLC
• F. Hoffmann-La Roche Ltd
• Guardant Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).
How can this report add value to an organization?
Workflow/Innovation Strategy: The gene fusion testing market, segmented by indication, comprises solid tumors and hematological malignancies. Furthermore, the study provides a thorough analysis of the diverse applications of gene fusion testing in solid tumors, offering readers a comprehensive understanding of its role in identifying gene fusions linked to these specific cancer types.
Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic technique employed to identify and analyze specific genetic alterations in cancer cells. It occurs when two distinct genes, typically located on different chromosomes, fuse abnormally, creating a hybrid gene that generates a unique protein with modified functions.
Competitive Strategy: Key players in the global gene fusion testing market have been extensively analyzed and profiled in this study, including manufacturers. Furthermore, a detailed competitive benchmarking of these players has been performed to give readers a clear insight into how companies measure up against each other, presenting a comprehensive view of the market landscape.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
• Detailed secondary research to ensure maximum coverage of manufacturers/suppliers operational in a country.
• Exact revenue information, up to a certain extent, will be extracted for each company from secondary sources and databases. Revenues specific to product/service/technology will then be estimated for each market player based on fact-based proxy indicators as well as primary inputs.
• The currency conversion rate has been taken from the historical exchange rate of Oanda and/or other relevant websites.
• Any economic downturn in the future has not been taken into consideration for the market estimation and forecast.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year.
• The term "product" in this document may refer to "service" or "technology" as and where relevant.
• The term "manufacturers/suppliers" may refer to "service providers" or "technology providers" as and where relevant.
Primary Research
The key data points taken from the primary sources include:
• Validation and triangulation of all the numbers and graphs
• Validation of the report’s segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type
• Percentage split of individual markets for regional analysis
Secondary Research
Open Sources
• Food and Drug Administration (FDA), European Medical Agency (EMA), National Medical Product Administration (NMPA), Ministry of Health, Labor, and Welfare (MHLW), Pharmaceutical and Medical Devices Association (PMDA), Frontiers, and World Intellectual Property Organization (WIPO)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases
The key data points taken from the secondary sources include:
• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations
Global Gene Fusion Testing Market Industry Overview
The global gene fusion testing market is a critical component of molecular diagnostics and precision medicine, focused on identifying genetic alterations, specifically gene fusions, that contribute to the development of various diseases, particularly cancer. These tests detect gene rearrangements that may lead to abnormal protein functions, driving cancer progression. As the demand for advanced diagnostic technologies grows, the global gene fusion testing market has become essential in precision medicine, enabling the development of personalized treatments tailored to the unique genetic profiles of individual patients. This market plays a vital role in transforming cancer care, allowing for more targeted and effective therapies based on genetic findings.
In the global gene fusion testing market, several technologies such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR) are used to detect gene fusions in various cancers. As advancements continue, the global gene fusion testing market is expected to grow exponentially, offering new opportunities for early diagnosis, precise treatment selection, and improved patient outcomes. The rising demand for personalized medicine further propels the global gene fusion testing market, ensuring that patients receive treatments tailored to their genetic makeup, enhancing the effectiveness of therapies and minimizing side effects.
Market Lifecycle Stage
The global gene fusion testing market is experiencing significant growth, fueled by the rising prevalence of cancer associated with gene fusion mutations. The increasing demand for early detection, precise selection of targeted therapies, and personalized medicine is driving this expansion. Additionally, the growing adoption of gene fusion testing in clinical practice is further accelerating the need for these diagnostic tests in cancer care. As the global gene fusion testing market continues to evolve, it plays a crucial role in enabling more accurate and individualized treatment options for cancer patients, improving overall patient outcomes.
Impact
Gene fusion testing is a diagnostic method that employs molecular analysis to detect and examine genetic abnormalities known as gene fusions. These occur when two distinct genes from different chromosomal regions become abnormally joined, creating a hybrid gene. This fusion can result in the production of abnormal proteins or changes in gene expression, potentially contributing to the development of various diseases, including certain cancers. Cancer progression is influenced by multiple genetic alterations, such as mutations, deletions, amplifications, and rearrangements, with gene fusions being a key factor. The involvement of leading industry players, including Amoy Diagnostics Co., Ltd., Biocartis, Biocare Medical, LLC, Danaher Corporation, and F. Hoffmann-La Roche Ltd., is expected to drive further growth in the global gene fusion testing market.
In addition, AI-powered prediction models offer the potential to minimize the need for time-consuming and expensive laboratory assays by identifying patients who may require additional diagnostic testing. These models could also uncover previously undetected gene fusion events, improving the understanding of the genomic landscape of cancers and supporting the development of targeted therapeutic approaches in the global gene fusion testing market.
Market Segmentation:
Segmentation 1: by Category
• Research
• Diagnostic
Research to Continue its Dominance in the by Category Segment
In terms of category type, the research segment is anticipated to lead the global gene fusion testing market in FY2024. The increasing adoption of kits, assays, and accessories has greatly contributed to the growth and prominence of this segment. These research-specific assays and kits, primarily designed for use in research settings rather than diagnostic applications, are vital for scientists and researchers studying gene fusions and their involvement in various diseases, especially cancer. As demand for these tools continues to rise, the research segment is set to maintain its dominant position in the global gene fusion testing market.
Segmentation 2: by Technology
• NGS
• FISH
• PCR
• IHC
NGS to Continue its Dominance in the Technology Segment
Based on technology, the NGS (Next-Generation Sequencing) segment is projected to dominate the global gene fusion testing market in FY2024. NGS is an advanced and transformative technology that plays a pivotal role in gene fusion testing, providing high-throughput and accurate analysis of DNA and RNA sequences. In the context of gene fusion testing, NGS facilitates a comprehensive examination of genetic rearrangements, enabling the precise identification of fusion events between different genes with exceptional accuracy. As NGS continues to evolve, it is set to maintain its leading position in the global gene fusion testing market.
Segmentation 3: by Indication
• Solid Tumors
• Hematological Malignancies
Solid Tumors to Continue its Dominance in the Indication Segment
Based on indication, the solid tumors segment is anticipated to lead the global gene fusion testing market in FY2024. In oncology, gene fusion testing for solid tumors is crucial in molecular diagnostics, focusing on identifying specific gene fusions caused by chromosomal rearrangements or translocations within tumor cells. These gene fusions can result in the production of abnormal fusion proteins, which play a significant role in the progression and development of solid tumors. As the demand for precise cancer diagnostics increases, the solid tumors segment is expected to maintain its dominance in the global gene fusion testing market.
Segmentation 4: by End User
• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Laboratories
• Academic and Research Centers
Pharmaceutical and Biotechnology Companies to Continue its Dominance in the End User Segment
Based on end user, the pharmaceutical and biotechnology companies segment is expected to hold the largest share of the global gene fusion testing market in FY2024. These companies play a crucial role in the market, utilizing their expertise and resources to drive innovation and promote advancements in this rapidly evolving field. With a keen understanding of the significant potential of gene fusion testing, pharmaceutical and biotechnology companies are leading efforts to revolutionize cancer diagnostics and treatment strategies, ensuring continued growth and development in the global gene fusion testing market.
Segmentation 5: by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World
U.K. to Continue its Dominance as the Leading Country in Europe Region
Germany is the dominant market in Europe, with the U.K. projected to experience the highest growth rate. The U.K. has adopted a supportive approach towards the development of gene fusion testing technologies. Furthermore, the country is known for its robust academic and research institutions, which play a critical role in advancing genetic testing technologies and driving innovation in the global gene fusion testing market.
Demand - Drivers and Limitations
Market Demand Drivers:
• Growing Prevalence of Cancer Driven by Gene Fusion Mutations
• Expanding Use of Gene Fusion Testing in Targeted Therapy Development
• Global Increase in Research Funding Focused on Cancer Screening and Prevention
Market Restraints:
• Challenges Due to the Complexity of the Testing Process
• Issues with Standardization and Barriers in Reimbursement Policies
Market Opportunities:
• Growing Demand for Gene Fusion Testing in Clinical Research
• Utilizing Artificial Intelligence to Predict Gene Fusion Status Across Various Cancer Types
The gene fusion testing market is a crucial segment within the healthcare industry, dedicated to the development, production, and commercialization of tests and technologies aimed at detecting and analyzing gene fusions. This testing identifies abnormal fusion events where two distinct genes merge to form fusion proteins with modified functions, often linked to various diseases, particularly cancer. This study explores several core technologies that have driven advancements in gene fusion testing, including polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), and fluorescence in-situ hybridization (FISH). The expansion of the global gene fusion testing market is fueled by the ongoing introduction of innovative technologies and increasing investments and funding from both government and private sectors.
Gene Fusion Testing Market - A Global and Regional Analysis
Focus on Category, Technology, Indication, End User, and Region - Analysis and Forecast, 2025-2035
Frequently Asked Questions
Gene fusion testing is a diagnostic method used to identify genetic alterations in which two distinct genes fuse together, forming a hybrid gene. These fusion genes can result in abnormal protein production that may contribute to various cancers and other genetic disorders. Gene fusion testing plays a critical role in identifying therapeutic targets and guiding treatment decisions, particularly in precision medicine, by detecting genetic biomarkers associated with specific diseases.
Leading players in the gene fusion testing market are focusing on expanding their product portfolios, forming strategic partnerships, and enhancing research and development efforts. Companies are also working towards improving the accuracy and efficiency of gene fusion tests by integrating advanced technologies such as artificial intelligence (AI) and machine learning (ML) into their platforms. Partnerships between diagnostic labs and pharmaceutical companies are also becoming increasingly common to foster the development of targeted therapies based on gene fusion data.
A new entrant could focus on developing high-throughput and cost-effective gene fusion testing solutions that offer faster results with minimal sample requirements. Additionally, integrating artificial intelligence and machine learning for data analysis and offering tests for less common or emerging gene fusions could provide a competitive edge. Collaboration with academic research institutions and biotech companies for clinical validation is another promising strategy for entering this market.
Key trends in the gene fusion testing market include the increasing adoption of next-generation sequencing (NGS) technologies for gene fusion detection, the rise in personalized medicine, and advancements in liquid biopsy techniques. Furthermore, the growing focus on cancer research and targeted therapies, coupled with the development of minimally invasive diagnostic methods, is expected to drive the demand for gene fusion testing solutions.
This report will be useful for diagnostic companies, pharmaceutical companies, biotechnology firms, and healthcare providers involved in gene fusion testing or precision medicine. It is also highly relevant for investors seeking insights into the potential growth of the gene fusion testing market. Additionally, academic institutions and researchers focused on genetics, oncology, and molecular diagnostics can benefit from the comprehensive analysis provided in this report.